Amniotic Membrane Transplantation in Infectious Corneal Ulcer

Kim, Jae-Soon; Kim, Jae-Chan; Hahn, Tae Won; Park, Woo-Chan

doi:10.1097/00003226-200110000-00010

Cited by 128 publications

(108 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our experience, AMT could effectively heal the ulcers similar to other reports. [21][22][23][24][25][26] The healing was with corneal epithelial phenotype in six eyes. Three eyes healed by conjunctival epithelial phenotype which can be explained by the difference in the cause of the epithelial defects, associated problems and the previous treatments, and thus by the extent of initial damage to the ocular surface.…”

Section: Discussionmentioning

confidence: 99%

Corneal sensitivity and ocular surface changes following preserved amniotic membrane transplantation for nonhealing corneal ulcers

Doğru

Yıldız

Baykara

et al. 2003

Eye

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Corneal sensitivity and ocular surface changes following preserved amniotic membrane transplantation for nonhealing corneal ulcers

Doğru

Yıldız

Baykara

et al. 2003

Eye

View full text Add to dashboard Cite

“…Curcumin was isolated from the rhizome of Curcuma longa and is a promising chemopreventive agent presently in phase I clinical trials [8]. Curcumin exhibits anticancer activities against range of cancers including skin, fore stomach, duodenal, and colon carcinogenesis [9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Corneal Neovascularization by Hydrazinocurcumin

Zhan¹,

Zhu²,

Zhang³

2016

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the effect of hydrazinocurcumin on a human vascular endothelial growth factor (VEGF)-induced corneal neovascularization in rabbit model. Methods: Murine corneal neovascularization (CorNV) was induced via two intrastromal implantations of VEGF polymer 2 mm from the limbus. Hydrazinocurcumin was administered topically on the cornea 4 times daily for 7 days. The therapeutic effects of hydrazinocurcumin were evaluated daily using slitlamp. At the end of the treatment, the corneas were harvested for H&E staining, masson trichrome staining, immuno-histochemical study, and semi-quantification reverse transcription polymerase chain reaction (RT-PCR) was utilized for measurement of inflammation-related molecules. Results: Topical application of hydrazinocurcumin had significant therapeutic effects on CorNV Hydrazinocurcumin extract treatment was more effective in suppressing CorNV in terms of vessel length and levels of cluster of differentiation 31 (CD31) proteins or angiogenesis-related genes such as VEGF, matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9). The average length of vessels in hydrazinocurcumin-treated group was only 17 % of that in the control group.Hydrazinocurcumin also inhibited inflammation more markedly by more effectively inhibiting mononuclear and polymorphonuclear cell infiltration into the corneal stroma and reducing levels of stromal cell-derived factor-1 (SDF1), tumor necrosis factor-alpha (TNFα) and macrophage inflammatory . In addition, the corneas of hydrazinocurcumin group had a more regular and compact architecture of collagen with thinner corneal thickness than those of the untreated group. Conclusion: Hydrazinocurcumin inhibited human vascular endothelial growth factor (VEGF)-induced rabbit corneal neovascularization and thus can potentially be used for its treatment.

show abstract

“…üç bakteriyel keratit olgusunu antibiyotik tedavisine ilave olarak AMT uygulayarak başarıyla tedavi etmişlerdir. 30,31 Mikrobik keratitli 14 olgumuzun %85'inde AMT'den sonra iyileşme ve epitelizasyon gerçekleşmiştir.…”

Section: Discussionunclassified

Amniotic Membrane Transplantation in Corneal and Conjunctival Diseases

Acer¹,

Akkaya²,

Tök³

et al. 2012

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

Ö ÖZ ZE ET T AAm ma aç ç: : Amniyotik membran transplantasyonunun kornea ve konjonktiva hastalıklarının tedavisindeki etkinliğini ortaya koymak. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Ocak 2004 ve Ekim 2007 tarihleri arasında kornea ve konjonktiva hastalıkları nedeniyle örtme ("overlay") tekniği ile amniyotik membran transplantasyonu uygulanan 76 hastanın (76 göz) dosyaları retrospektif olarak incelendi. Olgular dört gruba ayrıldı: Grup 1 (nö-rotrofik keratit), Grup 2 (mikrobik keratit), Grup 3 (büllöz keratopati) ve Grup 4 (semblefaron, konjonktival tümör, kimyasal yanık, açıkta kalma keratopatisi, bant keratopati, romatoid artrit ve vernal keratokonjonktivite bağlı kornea ülseri). Yaş, cinsiyet, görme keskinliğindeki değişme (Snellen eşeli ile), epitelizasyon başarısı, epitelizasyon süresi, takip süresi değerlendirilen değişkenlerdi. B Bu ul lg gu ul la ar r: : Hastaların ortalama yaşı 51,96±21,83 yıl idi (6-85 yaş; %67,2 erkek, %32,8 kadın). Ortalama takip süresi 8,05±6,19 (3-27) ay idi. Amniyotik membran transplantasyonu en sık nörotrofik keratit (%28,95) nedeniyle uygulandı. Olguların %18,42'sini mikrobik keratitler, %17,1'ini semblefaron, %13,16'sını büllöz keratopati ve %22,37'sini diğer-leri oluşturmaktaydı. Kornea hastalıklarının %80,2'sinde epitelizasyon ortalama 20,06±7,40 günde gerçekleşti. Gruplar arasında ortalama epitelizasyon zamanı (p=0,72) ve epitelizasyon başarısı (p=0,14) açısından istatistiksel olarak anlamlı fark saptanmadı. Görme keskinliği 30 hastada (%51,7) arttı, 22 hastada (%37,9) aynı seviyede kaldı, 6 hastada (%10,4) ise azaldı. Amniyotik membran transplantasyonu sonrasında öncesine göre görme keskinliğinde istatistiksel olarak anlamlı artış sağlandı (p<0,001). S So on nu uç ç: : Amniyotik membran transplantasyonu, çeşitli kornea ve konjonktiva hastalıklarının tedavisinde tek başına veya limbal kök hücre transplantasyonu ve keratoplasti ile birlikte uygulandığında etkili bir yöntemdir.A An na ah ht ta ar r K Ke el li im me el le er r: : Amniyon, amniyos; yanıklar, kimyasal; korneal ülser; keratit; konjonktivit, allerjik; konjonktival tümörler A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : To reveal the effectiveness of amniotic membrane transplantation in corneal and conjunctival diseases. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : The records of 76 patients (76 eyes) who underwent amniotic membrane transplantation using an overlay technique between January 2004 and October 2007 were evaluated retrospectively. The patients were divided into four groups: Group 1 (neurotrophic keratitis), Group 2 (microbial keratitis), Group 3 (bullous keratopathy) and Group 4 (symblepharon, conjunctival tumor, chemical burn, exposure keratopathy, band keratopathy, rheumatoid arthritis and vernal keratoconjunctivitis associated ulcer). The age, gender, change in visual acuity (according to Snellen chart), epithelization success, elapsed time for epithelization, and follow-up time were the outcome measures. R Re es su ul lt ts s: : The mean age of the patients wa...

show abstract

Amniotic Membrane Transplantation in Infectious Corneal Ulcer

Abstract: Amniotic membrane transplantation seems to be a useful adjunctive surgical procedure for the management of infectious corneal ulcer by promoting wound healing and reducing inflammation.

Cited by 128 publications

References 17 publications

Corneal sensitivity and ocular surface changes following preserved amniotic membrane transplantation for nonhealing corneal ulcers

Corneal sensitivity and ocular surface changes following preserved amniotic membrane transplantation for nonhealing corneal ulcers

Inhibition of Corneal Neovascularization by Hydrazinocurcumin

Amniotic Membrane Transplantation in Corneal and Conjunctival Diseases

Contact Info

Product

Resources

About